Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Farshid Dayyani

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
The Oncologist|July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaGregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
Oncoimmunology|September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsTian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Cancers|February 27, 2026
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant TherapySakti Chakrabarti, Stacey A Cohen, Antony Tin, et al.
Annals of Surgery|August 7, 2025
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon CancerStacey A Cohen, Vasily N Aushev, George Laliotis, et al.
The Lancet. Gastroenterology & Hepatology|June 1, 2024
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo-Youn Oh, Aiwu Ruth He, Mohamed Bouattour, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
The Oncologist|July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaGregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
Oncoimmunology|September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsTian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Cancers|February 27, 2026
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant TherapySakti Chakrabarti, Stacey A Cohen, Antony Tin, et al.
Annals of Surgery|August 7, 2025
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon CancerStacey A Cohen, Vasily N Aushev, George Laliotis, et al.
The Lancet. Gastroenterology & Hepatology|June 1, 2024
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo-Youn Oh, Aiwu Ruth He, Mohamed Bouattour, et al.
Pageof 12